Related Experiment Video

Updated: Jul 19, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk

Tefurumi Kato1, Kazuto Nishio

  • 1Shien-Lab and Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. tkato@ncc.go.jp

Respirology (Carlton, Vic.)
|October 21, 2006
PubMed

Insights

Gefitinib and erlotinib target epidermal growth factor receptor (EGFR) for advanced lung cancer. Clinical factors and EGFR mutations predict response, while certain conditions increase risks, necessitating careful benefit-risk assessment.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Gefitinib and erlotinib are small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase.
  • While not synergistic with cytotoxic drugs in first-line treatment for advanced non-small cell lung cancer (NSCLC), erlotinib showed survival benefits in recurrent cases.
  • Clinical and genetic factors influence treatment response and the risk of interstitial lung disease.

Purpose of the Study:

  • To review the clinical and genetic factors influencing the efficacy and toxicity of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer.
  • To highlight the importance of personalized medicine in NSCLC treatment based on patient-specific characteristics.

Main Methods:

  • Literature review of studies on gefitinib and erlotinib in advanced non-small cell lung cancer.
  • Analysis of clinical factors (gender, histology, smoking history) and genetic markers (EGFR mutations) associated with treatment response.
  • Examination of risk factors for EGFR TKI-induced interstitial lung disease, particularly in the Japanese population.

Main Results:

  • Erlotinib demonstrated survival prolongation compared to best supportive care in patients with recurrent NSCLC.
  • Positive EGFR mutations (exons 18-24) strongly correlate with treatment response.
  • Pre-existing idiopathic pulmonary fibrosis, male gender, and smoking history are risk factors for interstitial lung disease in Japanese patients.

Conclusions:

  • EGFR mutation status is a key predictor of response to EGFR TKIs in NSCLC.
  • Patient ethnicity and specific clinical factors influence the risk of severe adverse events like interstitial lung disease.
  • Prescribing EGFR TKIs requires careful assessment of individual patient benefits and risks, considering both efficacy and potential toxicity.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...